KalVista Pharmaceuticals, Inc.

Fundamentals4.0
Price Action7.0
News Sentiment6.0
AI Rating
5.0

Key Drivers

  • Gross Margin
  • Negative Equity
  • Cash Burn

AI
AI Summary

5.0

KALV should now be viewed primarily as an event-driven merger-arb around Chiesi's $27/share offer, with upside largely capped and the real decision point centered on whether the remaining spread compensates for deal-close, legal, and approval risk given the weak standalone profile of ongoing cash burn and negative equity.

M&A‍
DealRisk
CashBurn

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

4.0

Key Financial Insights:

  • Gross Margin
  • Negative Equity
  • Cash Burn

KALV shows strong product economics and liquidity, but persistent operating losses, negative free cash flow, and a negative equity position make the business financially high risk. ക ക

cashflow
solvency

Price Behavior

7.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Gap-up breakout
  • Tight consolidation
  • Resistance ceiling

Over the last month, KALV remains in a clear uptrend after a sharp gap-up, but the stock has stalled in a tight range near $26.80, so a breakout above resistance is needed for further upside.

bullish
breakout
Support Level: $26.65–$26.66
Resistance Level: $26.80

Sharp gap up from $19.24 on 2026-04-28 to $26.67 on 2026-04-29

Sentiment & News

6.0

Key News Insights:

  • Takeover premium
  • Legal scrutiny
  • Insider sales

Chiesi Group's $1.9 billion all-cash acquisition of KalVista sparked a sharp share move, while shareholder law firms quickly opened fairness and process reviews amid prior insider selling.

Takeover
ShareholderRisk

The acquisition news is bullish for KALV in the near term, but legal investigations could create headline risk and pressure deal certainty